Ultragenyx Pharmaceutical stock has plummeted this week, after its experimental treatment for an uncommon genetic bone disease failed in late-stage trials.
United States (National)
Josh Nathan-Kazis
Geo Focus
Coverage Attributes:
Beta
Informative:
49
%
Data Driven:
24
%
Opinion:
8
%
Reviews:
5
%
Promotional:
4
%
Themes Covered:
Not enough data
Pitching Insights
Josh Nathan-Kazis primarily focuses on investment analysis and data-driven reporting within the healthcare and pharmaceutical industry in the United States. He seems to be interested in providing insights into stock performance, market trends, and major company developments.
If you have expert knowledge in the healthcare or pharmaceutical sectors with a focus on stocks, earnings reports, FDA approvals, or other related financial aspects of these industries, your input could be valuable for Josh's coverage.
Consider offering data-backed insights or exclusive information regarding major companies' financial performance or regulatory developments within the U.S. healthcare sector when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
